Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Pharmacy
Published in: International Journal of Clinical Pharmacy 4/2008

01-08-2008 | Case Report

Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report

Authors: Tiene G. M. Bauters, Joris Verlooy, Hugo Robays, Geneviéve Laureys

Published in: International Journal of Clinical Pharmacy | Issue 4/2008

Login to get access

Abstract

We present a case of severe mucositis due to a drug–drug interaction between methotrexate (MTX) and omeprazole in an adolescent with Acute Lymphatic Leukemia (ALL). In view of the prevalence of MTX in many cytotoxic protocols, and the frequent use of omeprazole in the (ambulatory) oncology setting, we believe that this case-report is worth mentioning.
Literature
1.
Micromedex, Health Care Series. Thomson Health Care, Greenwood Village, Colorado, USA, 2007.
2.
Peyriere H, Cociglio M, Margueritte G, Vallat C, Blayac JP, Hillaire-Buys D. Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother. 2004;38:422–7.PubMedCrossRef
3.
Tortajada-Ituren J, Ordovas-Baines J, Llopis-Salvia P, Jimenez-Torres N. High-dose methotrexate-doxycycline interaction. Ann Pharmacother. 1999;33:804–8.PubMedCrossRef
4.
5.
6.
EsPhALL: European Intergroup Study on post-induction treatment of PhALL (Phase II/III study).
7.
Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34:1024–7.PubMedCrossRef
8.
Reid T, Yuen A, Catolico M, et al. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol. 1993;33:82–4.PubMedCrossRef
9.
Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate clearance. Cancer Chemoter Pharmacol. 1999;44:88–9.CrossRef
10.
Metadata
Title
Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report
Authors
Tiene G. M. Bauters
Joris Verlooy
Hugo Robays
Geneviéve Laureys
Publication date
01-08-2008
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 4/2008
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-008-9204-9

Other articles of this Issue 4/2008

International Journal of Clinical Pharmacy 4/2008 Go to the issue

Research Article

The general pharmacy work explored in The Netherlands

Case Report

Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma

Research Article

Evaluation of frequently used drug interaction screening programs

Commentary

A discussion paper on self-care and its implications for pharmacists

Research Article

Factors contributing to the development of hypophosphataemia when refeeding using parenteral nutrition

Abstracts

Progress in practice UKCPA residential symposium
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits